This trial is evaluating whether Bimatoprost (SR) will improve 2 primary outcomes in patients with Glaucoma, Suspect. Measurement will happen over the course of Baseline up to 48 months.
This trial requires 490 total participants across 2 different treatment groups
This trial involves 2 different treatments. Bimatoprost (SR) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Glaucoma is a disease that causes visual impairment, primarily due to retinal damage. One of the main causes is an increased pressure in the eye. It can be controlled with the use of proper treatment and/or lifestyle changes. People can decrease their risk of developing glaucoma by keeping an eye on diet and exercising at regular intervals.\n" - Anonymous Online Contributor
"About 1.3 million individuals in the United States are estimated to be affected by glaucoma or ocular hypertension. question: Is the incidence of [cataract](https://www.withpower.com/clinical-trials/cataract) rising as the population ages in the United States : a study of Medicare beneficiaries ages 65 to 94 years in 1990? answer: The projected increased incidence of cataracts in the U.S. is expected to be evident in the next five to ten years. The incidence rate of cataract surgery over the age of 65 years is anticipated to increase by 20% per year. This phenomenon should be considered in the delivery of preventive health services to the growing population of older Americans." - Anonymous Online Contributor
"Glaucoma, open-angle, is not a single disease, but resembles many conditions where it causes damage to the optic nerve. The most important risk factors for open-angle glaucoma, open-angle glaucoma, are age and primary open-angle angle closure. Secondary open-angle glaucoma occurs following the development of ocular hypertension, often in response to the presence of a risk, such as angle closure or angle dystocia; glaucoma can also be due to the breakdown of the trabecular meshwork and the loss of the vascular network within the eye." - Anonymous Online Contributor
"Glaucoma is the most common ocular disease and is usually detected due to symptoms, with signs in the form of blurry vision, decreased visual acuity, and optic disc haemorrhage being common. Patients with glaucoma often have an insidious onset of vision loss, and they can be asymptomatic for years before diagnosis. Clinical characteristics of glaucoma include an increased intraocular pressure, an abnormal optic disc, an abnormal vertical cup to disc ratio, a thin nerve fibre layer, and small retinal venules. Glaucoma can often be asymptomatic for years before symptoms become apparent." - Anonymous Online Contributor
"The data suggest that there is no cure for glaucoma, open-angle and that the only benefit is one time surgery. It can happen; as a last resort, where there is evidence of uncontrolled worsening and a visual field loss, or when the medical management is obviously inadequate (e.g. unresponsive optic neuropathy, severe pain, high IOP or angle closure/scarred iris) or is there a risk to the visual function of the eye (e.g. angle closure glaucoma, uveofibrosis, retinal detachment or cataract)." - Anonymous Online Contributor
"When glaucoma starts in childhood or adolescence, glaucoma medications do not appear to change the risk of subsequent cataract, further glaucoma, or a retinal detachment. When glaucoma starts in adulthood, glaucoma medications appear to change the risk of future cataract." - Anonymous Online Contributor
"A higher dose of 0.003 % bimatoprost in an ocular solution may cause blurred vision. Moreover, the most common adverse effect of bimatoprost was ocular pain. As bimatoprost has been used at lower concentrations since it was approved in the US, it deserves further consideration." - Anonymous Online Contributor
"The efficacy and safety profile of 0.025 mg Bimatoprost in controlling ocular hypertension is consistent with the FDA label and the AURORA study of Bimatoprost 0.01--0.03 mg vs preservative-free aqueous diclofenac and Bimatoprost 0.0001--0.003 mg vs preservative-free timolol (0.01--0.03 mg) in patients with advanced open angle glaucoma. Recent findings suggest that 0.025 mg Bimatoprost is a clinically appropriate dose for the treatment of ocular hypertension associated with open-angle glaucoma." - Anonymous Online Contributor
"There are no prospective, controlled studies on bimatoprost available in the literature, and the results of these studies have thus far come only from a small number of individual patients. Moreover, the efficacy and side effects are limited data for this substance. Therefore, further evaluations in this area should be conducted." - Anonymous Online Contributor
"While the most common side effects were eye inflammation (6,000%) and blurry vision (4,900%), 1.2% of persons discontinuing bimatoprost discontinued due to these side effects. One percent of persons discontinued use of bimatoprost because they were dissatisfied, with less than 1% not achieving improvements in IOP. For most, the improvement in IOP was statistically significant." - Anonymous Online Contributor
"The most common clinical indications listed were glaucoma with or without open angle, open angle glaucoma and ocular hypertension. Treatment with bimatoprost (sr) is used most efficiently by glaucoma specialists for patients who have poor VA or who have poor ocular hypertension control with a combination of other ocular hypotensive drugs. The drug is particularly helpful in patients who have open-angle glaucoma. In order to qualify for bimatoprost (sr) treatment, patients must have open angle glaucoma with uncontrolled intraocular pressure and/or VA with a minimum PVR20." - Anonymous Online Contributor
"Clinical trials should be offered to patients who have had glaucoma for many years, are candidates for procedures that were not successful, if they have progressive vision loss, and should be offered after a detailed history." - Anonymous Online Contributor